Mr. Dave Mason reports

HLS THERAPEUTICS INCREASES NORMAL COURSE ISSUER BID

HLS Therapeutics Inc. has filed with the Toronto Stock Exchange (the TSX), and the TSX has accepted, an amended notice of intention regarding its existing normal course issuer bid (the NCIB) to increase the number of common shares that may be repurchased for cancellation from 1.5 million to 1,872,685 common shares, representing approximately 10 per cent of the public float as of June 12, 2026, the maximum amount allowable under the rules of the TSX.

The NCIB will continue until the earliest of: (i) the close of trading on June 24, 2027, (ii) the date upon which HLS acquires the maximum number of common shares permitted under the NCIB, and (iii) the date upon which HLS provides written notice of termination of the NCIB to the TSX. Daily purchases pursuant to the NCIB will be limited to 2,080 common shares, other than purchases made pursuant to the block purchase exception, based on the applicable average daily trading volume on the TSX for six months ending May 29, 2026, of 8,321 common shares.

Purchases of common shares under the NCIB will be made by Raymond James Ltd. based on the parameters prescribed by the TSX, the provisions of the company's credit agreement and applicable Canadian securities laws at a price per common share equal to the market price at the time of acquisition. All common shares acquired by the company under the NCIB will be cancelled.

The company has also entered into an automatic share purchase plan (the ASPP) with Raymond James to allow for the purchase of common shares under the NCIB at times when the company would ordinarily not be permitted to purchase shares due to regulatory restrictions or self-imposed blackout periods.

HLS believes that any purchases pursuant to the NCIB, if considered advisable, will be in the best interests of the company and will be a desirable use of corporate funds. To date, HLS repurchased for cancellation 1,054,037 common shares at a weighted average price of $3.90 per common share since the commencement of the NCIB.

About HLS Therapeutics Inc.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted, and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong record of success in these therapeutic areas and at managing products in each of these life cycle stages.

We seek Safe Harbor.